Thermo Fisher Scientific financials
$679.61+0.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 27 | Q1 '26 Mar 28 | Q4 '25 Dec 31 | Q3 '25 Sep 27 | Q2 '25 Jun 28 | Q1 '25 Mar 29 | Q4 '24 Dec 31 | Q3 '24 Sep 28 | Q2 '24 Jun 29 | Q1 '24 Mar 30 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.99B | $11.01B | $12.21B | $11.12B | $10.86B | $10.36B | $11.39B | $10.60B | $10.54B | $10.35B | $10.89B | $10.57B |
| Gross profit | $4.88B | $4.43B | $5.01B | $4.58B | $4.41B | $4.24B | $4.82B | $4.33B | $4.35B | $4.21B | $4.39B | $4.32B |
| Gross margin | 40.7% | 40.3% | 41.0% | 41.2% | 40.6% | 40.9% | 42.3% | 40.8% | 41.2% | 40.6% | 40.4% | 40.8% |
| Operating income | $2.09B | $1.86B | $2.26B | $1.94B | $1.83B | $1.72B | $2.02B | $1.84B | $1.82B | $1.66B | $1.85B | $1.86B |
| Net income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | $1.51B | $1.83B | $1.63B | $1.55B | $1.33B | $1.63B | $1.72B |
| Net margin | 14.5% | 15.0% | 16.1% | 14.5% | 14.9% | 14.5% | 16.1% | 15.4% | 14.7% | 12.8% | 15.0% | 16.2% |
| Diluted EPS | $4.68 | $4.43 | $5.21 | $4.27 | $4.28 | $3.98 | $4.80 | $4.25 | $4.04 | $3.46 | $4.20 | $4.42 |
| EBITDA | $2.09B | $2.65B | $3.03B | $3.60B | $1.74B | $2.52B | $2.99B | $3.69B | $1.62B | $2.53B | $1.93B | $2.80B |
| Operating cash flow | $2.12B | $1.19B | $3.46B | $2.24B | $1.40B | $723.0M | $3.29B | $2.16B | $1.96B | $1.25B | $3.72B | $2.41B |
| Free cash flow | $1.67B | $817.0M | $2.99B | $1.83B | $1.10B | $361.0M | $2.81B | $1.89B | $1.66B | $903.0M | $3.32B | $2.08B |
| Diluted shares | 371.0M | 373.0M | 377.0M | 378.0M | 378.0M | 379.0M | 381.0M | 384.0M | 383.0M | 384.0M | 388.0M | 388.0M |
Balance sheet
| Period end | Jun 27 | Mar 28 | Dec 31 | Sep 27 | Jun 28 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.06B | $3.25B | $9.85B | $1.98B | $4.58B | $4.01B |
| Short-term investments | $0.00 | $2.0M | $253.0M | $1.56B | $1.81B | $1.56B |
| Total debt | $42.55B | $43.16B | $39.38B | $35.68B | $35.23B | $31.27B |
| Total assets | $113.17B | $113.28B | $110.34B | $103.02B | $101.23B | $97.32B |
| Total liabilities | $60.37B | $61.22B | $56.81B | $51.87B | $50.63B | $47.65B |
| Shareholders' equity | $52.69B | $51.94B | $53.41B | $51.02B | $50.48B | $49.55B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology